Zobrazeno 1 - 10
of 42
pro vyhledávání: '"J P, Cegielski"'
Autor:
Julia V. Ershova, Grigory V. Volchenkov, Tatiana R. Somova, Tatiana A. Kuznetsova, Natalia V. Kaunetis, Dorothy Kaminski, Olga V. Demikhova, Larisa N. Chernousova, Irina A. Vasilyeva, Eleanor M. Kerr, J. Peter Cegielski, Ekaterina V. Kurbatova
Publikováno v:
BMC Infectious Diseases, Vol 20, Iss 1, Pp 1-9 (2020)
Abstract Background The main advantage of GeneXpert MTB/RIF® (Xpert) molecular diagnostic technology is the rapid detection of M.tuberculosis DNA and mutations associated with rifampicin (RIF) resistance for timely initiation of appropriate treatmen
Externí odkaz:
https://doaj.org/article/86f88f08025e43cd9740d3c00a5f6273
Autor:
S E, Smith-Jeffcoat, K D, Eisenach, M, Joloba, W, Ssengooba, C, Namaganda, M, Nsereko, B, Okware, J S, Cavanaugh, J P, Cegielski
Publikováno v:
The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease. 26(11)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::7bc5ce2950253c77947a938cc8586111
https://pubmed.ncbi.nlm.nih.gov/36281051
https://pubmed.ncbi.nlm.nih.gov/36281051
Autor:
J. Peter Cegielski
Publikováno v:
Revista Peruana de Medicina Experimental y Salud Pública, Vol 35, Iss 1, Pp 110-7 (2018)
Multidrug-resistant (MDR) tuberculosis (TB) emerged shortly after introduction of rifamycins in the 1960s; isoniazid resistance had already emerged by the mid-1950s. Without these two drugs, tuberculosis is very difficult and costly to treat, with un
Externí odkaz:
https://doaj.org/article/5d5e2cef452e43b3bd4525498d6ab4fa
Autor:
J. R. Campbell, E. D. Chan, L. F. Anderson, M. Bonnet, S. K. Brode, J. P. Cegielski, L. Guglielmetti, R. Singla, G. J. Fox, A. Skrahina, D. Rodrigues, L. Kuksa, P. Viiklepp, D. Menzies
Publikováno v:
The International Journal of Tuberculosis and Lung Disease. 27:338-340
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::588ab4744d33902381b2b191983fda6b
https://doi.org/10.5588/ijtld.22.0678
https://doi.org/10.5588/ijtld.22.0678
Autor:
S. E. Smith-Jeffcoat, K. D. Eisenach, M. Joloba, W. Ssengooba, C. Namaganda, M. Nsereko, B. Okware, J. S. Cavanaugh, J. P. Cegielski
Publikováno v:
The International Journal of Tuberculosis and Lung Disease. 26:1058-1064
SETTING: Mulago Hospital, Kampala, Uganda.OBJECTIVE: To quantify Mycobacterium tuberculosis in sputum during the first 8 weeks of pulmonary multidrug-resistant TB (MDR-TB) treatment.DESIGN: We enrolled consecutive adults with pulmonary MDR-TB treated
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9663027b829dad9e59a9803eea5e442a
https://doi.org/10.5588/ijtld.21.0741
https://doi.org/10.5588/ijtld.21.0741
Publikováno v:
Emerging Infectious Diseases, Vol 22, Iss 9, Pp 1529-1536 (2016)
We analyzed data for a retrospective cohort of patients treated for extensively drug-resistant tuberculosis in 2 provinces in South Africa and compared predictors of treatment outcome in HIV-positive patients who received or had not received antiretr
Externí odkaz:
https://doaj.org/article/53fbd89ecb064f01b69692b783f72eee
Autor:
Julia Ershova, Grigory V. Volchenkov, Dorothy A. Kaminski, Tatiana R. Somova, Tatiana A. Kuznetsova, Natalia V. Kaunetis, J. Peter Cegielski, Ekaterina V. Kurbatova
Publikováno v:
Emerging Infectious Diseases, Vol 21, Iss 11, Pp 2048-2051 (2015)
We studied the epidemiology of drug-resistant tuberculosis (TB) in Vladimir Region, Russia, in 2012. Most cases of multidrug-resistant TB (MDR TB) were caused by transmission of drug-resistant strains, and >33% were in patients referred for testing a
Externí odkaz:
https://doaj.org/article/aa348f5a43094a62ab6e4c06e58b494d
Autor:
Ekaterina V. Kurbatova, Tracy Dalton, Julia Ershova, Thelma E. Tupasi, Janice Campos Caoili, Martie L. van der Walt, Charlotte L. Kvasnovsky, Martin Yagui, Jaime Bayona, Carmen Contreras, Vaira Leimane, Laura E. Via, HeeJin Kim, Somsak Akksilp, Boris Y. Kazennyy, Grigory V. Volchenkov, Ruwen Jou, Kai Kliiman, Olga V. Demikhova, J. Peter Cegielski
Publikováno v:
Emerging Infectious Diseases, Vol 21, Iss 6, Pp 977-983 (2015)
Data from a large multicenter observational study of patients with multidrug-resistant tuberculosis (MDR TB) were analyzed to simulate the possible use of 2 new approaches to treatment of MDR TB: a short (9-month) regimen and a bedaquiline-containing
Externí odkaz:
https://doaj.org/article/4f50de4590284b6b880422a28b67b69a
Autor:
Sarah E. Smith, Julia Ershova, Natalia Vlasova, Elena Nikishova, Irina Tarasova, Platon Eliseev, Andrey Maryandyshev, Igor G. Shemyakin, Ekaterina V. Kurbatova, J. Peter Cegielski
Publikováno v:
Emerging Infectious Diseases, Vol 21, Iss 6, Pp 1002-1011 (2015)
Acquired resistance to antituberculosis drugs decreases effective treatment options and the likelihood of treatment success. We identified risk factors for acquisition of drug resistance during treatment for multidrug-resistant tuberculosis (MDR TB)
Externí odkaz:
https://doaj.org/article/b85179134aaa4c1791e2e8d9b2095ed8
Autor:
Courtney M Yuen, Ekaterina V Kurbatova, Thelma Tupasi, Janice Campos Caoili, Martie Van Der Walt, Charlotte Kvasnovsky, Martin Yagui, Jaime Bayona, Carmen Contreras, Vaira Leimane, Julia Ershova, Laura E Via, HeeJin Kim, Somsak Akksilp, Boris Y Kazennyy, Grigory V Volchenkov, Ruwen Jou, Kai Kliiman, Olga V Demikhova, Irina A Vasilyeva, Tracy Dalton, J Peter Cegielski
Publikováno v:
PLoS Medicine, Vol 12, Iss 12, p e1001932 (2015)
BackgroundFor treating multidrug-resistant tuberculosis (MDR TB), the World Health Organization (WHO) recommends a regimen of at least four second-line drugs that are likely to be effective as well as pyrazinamide. WHO guidelines indicate only margin
Externí odkaz:
https://doaj.org/article/ace629e2383f4a7b89c77c4a3526dd6b